Volume 13, Number 3—March 2007
Intermediate Vancomycin Susceptibility in a Community-associated MRSA Clone
|Antimicrobial drug||MIC (μg/mL) and CLSI interpretation|
|Nafcillin||>2 R||16 R||>2 R|
|Clindamycin||2 I||≤0.25 S||<0.25 S|
|Erythromycin||4 I||>8 R||>4 R|
|Trimethoprim-sulfamethoxazole||<0.5/9.5 S||≤0.25/5 S||<0.5/9.5 S|
|Tetracycline||<1 S||≤0.5 S†||<1 S|
|Rifampin||<1 S||≤0.25 S||<1 S|
|Ciprofloxacin||>2 R||>4 R||>2 R|
|Levofloxacin||>4 R||ND||>4 R|
|Gentamicin||<1 S||≤0.5 S||2 S|
|Vancomycin||<2 S||2 S||8 I 4–6 I‡|
|Linezolid||ND||2 S||2 S|
|Tigecycline||ND||0.125 S||0.125 S|
*CLSI, Clinical and Laboratory Standards Institute; R, resistant; I, intermediately resistant; S, susceptible; ND, not done.
†Susceptibility to doxycycline performed instead of to tetracycline.
‡Confirmatory susceptibility by E-test and growth on vancomycin (6 µg/mL) agar screen plates.
§Interpreted as nonsusceptible by the Centers for Disease Control and Prevention. Formal CLSI breakpoints for daptomycin resistance have not been established.
- Page created: June 29, 2010
- Page last updated: June 29, 2010
- Page last reviewed: June 29, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)